Figure 5

Changes in MBP, TNFR2, TLR4, and GAP43 protein expression following central anti-TNF treatment after SCI. (A) Quantification of MBP protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (B) Quantification of TNFR2 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (C) Quantification of TLR2 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. (D) Quantification of GAP43 protein expression in spinal cord tissue of saline-, XPro1595-, and etanercept-treated mice at 7 and 28 days after SCI. Data are normalized to β-actin protein expression. Representative experiments are shown. Results, expressed as percent of control, are the mean ± SEM of three animals per group. *P <0.05, **P <0.01, ***P <0.001, and ****P <0.0001 by one-way ANOVA with Tukey’s test.